Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Epic Sciences Inc patents


Recent patent applications related to Epic Sciences Inc. Epic Sciences Inc is listed as an Agent/Assignee. Note: Epic Sciences Inc may have other listings under different names/spellings. We're not affiliated with Epic Sciences Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "E" | Epic Sciences Inc-related inventors


Compositions and methods for prostate cancer analysis

The invention provides methods for diagnosing prostate cancer. The invention also provides methods for determining the prognosis and efficacy of steap1-adc therapy in patients with prostate cancer, specifically metastatic castration resistant prostate cancer (mcrpc).. ... Epic Sciences Inc

Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc)

The disclosure provides methods correlating intra-patient genomic heterogeneity of single ctcs with phenotypic heterogeneity in each of a population of prostate cancer (pca) patients.. . ... Epic Sciences Inc

Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies

The disclosure provides a method of predicting resistance to androgen receptor (ar) targeted therapy in a prostate cancer patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to identify circulating tumor cells (ctcs), and (b) based on said direct analysis further determining the presence of a biomarker signature that is predictive of resistance to ar targeted therapy in the prostate cancer patient, wherein the biomarker signature comprises ck+, ar+, nucleoli+ctcs in a subpopulation of said ctcs. The present disclosure also provides a method of predicting resistance to taxane-based chemotherapy in a prostate cancer patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to identify circulating tumor cells (ctcs), and (b) based on said direct analysis further determining the presence of a biomarker signature that is predictive of resistance to taxane-based chemotherapy in the prostate cancer patient, wherein the biomarker signature comprises ck+, ar−, nucleoli+, small size in a subpopulation of said ctcs.. ... Epic Sciences Inc

Circulating tumor cell diagnostics for identification of resistance to androgen receptor targeted therapies

The disclosure provides a method of predicting de novo resistance to androgen receptor (ar) targeted therapy in a tumor of a prostate cancer patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characteristization of nucleated cells in a blood sample obtained from the patient to generate circulating tumor cell (ctc) data, wherein the analysis comprises determining a measurable feature of a panel of traditional and non-traditional ctc biomarkers for de novo resistance to androgen receptor (ar) targeted therapy, and (b) evaluating the ctc data to determine the probability of de novo resistance to the ar targeted therapy in the tumor of the prostate cancer patient. Further disclosed are the panel of traditional and non-traditional ctc biomarkers for the methods.. ... Epic Sciences Inc

Circulating tumor cell diagnostics for therapy targeting pd-l1

The disclosure provides a method for determining if a subject afflicted with cancer is a candidate for programmed death ligand-1 (pd-l1) targeted immunotherapy, which method comprises (a) providing a liquid biopsy sample obtained from the subject afflicted with cancer; (b) detecting ctcs in the liquid biopsy sample; (c) calculating what proportion of ctcs in the liquid biopsy express pd-l1; and (c) identifying the subject as a candidate for pd-l1 targeted immunotherapy based on an assessment that the proportion of the ctcs in the liquid biopsy that express pd-l1 exceeds a pre-determined threshold level.. . ... Epic Sciences Inc

Methods for analyzing rare circulating cells

The disclosure provides methods for analyzing rare circulating cells (rccs) at cellular and molecular level following their detection in non-enriched blood samples, methods of this disclosure serve as diagnostic methods for several disease conditions, including cardiovascular diseases and cancer.. . ... Epic Sciences Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Epic Sciences Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Epic Sciences Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###